Advocacy intelligence hub — real-time data for patient organizations
John Kirkwood
Dana-Farber Cancer Institute
Associazione Italiana per lo Studio del Pancreas
Abraxane: FDA approved
Treatment of metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.
National Cancer Institute (NCI)
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Abraxane
(paclitaxel protein-bound particles)Orphan drugAbraxis BioScience, LLC
Microtubule Inhibitor [EPC]
12.1 Mechanism of Action ABRAXANE is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubule...
Browse all Familial atypical multiple mole melanoma syndrome news →
John M Kirkwood, MD
University of Pittsburgh
Michael Goggins, MD, MB BCh BAO
Johns Hopkins University
📍 PHILADELPHIA, PA
Shaffer Mok, MD, MBS
Moffitt Cancer Center
📍 TAMPA, FL
Aimee Lucas, MD, MS
Icahn School of Medicine at Mount Sinai
Rolf Ehrnström
Immunovia, Inc.
Emmanouil Papanastasiou, Dr.
Assistant Professor
View all Familial atypical multiple mole melanoma syndrome specialists →